The road to consensus: considerations for the safe use and prescribing of COX-2-specific inhibitors

To the Editor: We agree that the "what", "how" and "who" of guideline development all deserve equal, explicit and systematic attention.1

Correspondence: nswtag@stvincents.com.au

1. Van der Weyden M. Clinical practice guidelines: time to move the debate from the how to the who [editorial]. Med J Aust 2002; 176: 304-305. <MJA full text>
2. Edmonds JP, Day RO, Bertouch JV. The road to consensus: considerations for the safe use and prescribing of COX-2-specific inhibitors. Med J Aust 2002; 176: 332-334. <MJA full text>
3. Current Opinion: Cox-2 inhibitors — the evidence. Darlinghurst: NSW Therapeutic Assessment Group, January 2001. Available at <http://www.clininfo.health.nsw.gov.au/nswtag/publications/posstats/COX%202.pdf>.
4. National Health and Medical Research Council. Guidelines for the development and implementation of clinical practice guidelines. Canberra: AGPS, 1995.
5. Wazana A. Physicians and the pharmaceutical industry. Is a gift ever just a gift? JAMA 2000; 283: 373-380.
6. Choudhry NK, Stelfox HT, Detsky AS. Relationships between authors of clinical practice guidelines and the pharmaceutical industry. JAMA 2002; 287: 612-617.

Online responses are no longer available. Please refer to our instructions for authors page for more information.